Share on StockTwits

Myriad Genetics (NASDAQ:MYGN) saw some unusual options trading on Tuesday. Traders acquired 557 call options on the company, AmericanBankingNews.com reports. This is an increase of approximately 220% compared to the typical volume of 174 call options.

Several analysts have recently commented on the stock. Analysts at SunTrust raised their price target on shares of Myriad Genetics from $22.00 to $26.00 in a research note on Monday, July 14th. Separately, analysts at RBC Capital raised their price target on shares of Myriad Genetics from $31.00 to $40.00 in a research note on Monday, June 30th. They now have a “sector perform” rating on the stock. Finally, analysts at Macquarie reiterated a “neutral” rating on shares of Myriad Genetics in a research note on Thursday, June 5th. They now have a $36.00 price target on the stock, down previously from $38.00. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $35.34.

Myriad Genetics (NASDAQ:MYGN) traded up 1.91% on Tuesday, hitting $39.00. The stock had a trading volume of 1,817,694 shares. Myriad Genetics has a 52 week low of $20.02 and a 52 week high of $42.50. The stock’s 50-day moving average is $37.69 and its 200-day moving average is $35.9. The company has a market cap of $2.918 billion and a price-to-earnings ratio of 16.23.

Myriad Genetics (NASDAQ:MYGN) last released its earnings data on Tuesday, August 12th. The company reported $0.48 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.46 by $0.02. The company had revenue of $188.80 million for the quarter, compared to the consensus estimate of $187.68 million. Analysts expect that Myriad Genetics will post $2.39 EPS for the current fiscal year.

Myriad Genetics, Inc (NASDAQ:MYGN) is a molecular diagnostic company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.